alexa Examining the Influence of Behavioral Factors on Compliance and Persistence with Glatiramer Acetate Injection for Relapsing-Remitting Multiple Sclerosis | Abstract
ISSN: 2155-9562

Journal of Neurology & Neurophysiology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Examining the Influence of Behavioral Factors on Compliance and Persistence with Glatiramer Acetate Injection for Relapsing-Remitting Multiple Sclerosis

MerriKay Oleen-Burkey1,2*, Gabriel Pardo3, Howard Zwibel4, Douglas Denney5

1 Health Outcomes Research Consulting and Writing, Outcomes Scribe, LLC, Kalamazoo, MI, USA

2 Formerly, Health Economics and Outcomes Research, Teva Neuroscience, Inc., Kansas City, MO, USA

3 MS Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

4 Neuroscience Consultants, Comprehensive Multiple Sclerosis Center, Coral Gables, FL, USA

5 Department of Psychology, University of Kansas, Lawrence, KS, USA

Corresponding Author:
MerriKay Oleen-Burkey, PhD
Outcomes Scribe, LLC, 664 Wynding Oaks
Kalamazoo, MI 49006
Tel: 913-302-1211
E-mail: [email protected]

Received date: February 06, 2014; Accepted date: May 20, 2014; Published date: May 25, 2014

Citation: Oleen-Burkey M, Pardo G, Zwibel H, Denney D (2014) Examining the Influence of Behavioral Factors on Compliance and Persistence with Glatiramer Acetate Injection for Relapsing-Remitting Multiple Sclerosis . J Neurol Neurophysiol 5:205. doi:10.4172/2155-9562.1000205

Copyright: © 2014 Oleen-Burkey M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Objective: To evaluate the relationship between compliance and persistence with glatiramer acetate (GA) and
the behavioral variables in the transtheoretical model of change.
Methods: Patients diagnosed with relapsing-remitting multiple sclerosis and being treated with GA for the first
time, whether treatment-naïve (TN) or treatment-experienced (TE), were eligible for this prospective, observational,
12-week study. Institutional Review Board approval was obtained for each of 32 US study sites, and written informed
consent was obtained for all patients prior to study procedures. Four office visits were required. Study procedures
included baseline self-injection training and patient-reported behavioral variable surveys. Injection competence and
medication compliance and persistence were assessed at weeks 4 and 12.
Results: A total of 257 patients were enrolled; 80.9% were female, 81.6% white, and 60.0% TN. The evaluable
population included 146 TN patients and 88 TE patients having discontinued beta-interferons. TE patients were at a
significantly higher readiness stage, were less concerned about the negative aspects of self-injection, but had lower
levels of MS self-efficacy than TN patients. While compliance and persistence rates did not differ between TN and
TE groups, there were differences in outcome predictors. For the TN patients both higher self-injection competence
at baseline and improvement in self-injection competence over the first month of therapy were predictive of better
compliance and persistence with GA. Separate from injection competence, higher levels of functional self-efficacy
were directly associated with better persistence in TN patients. None of the behavioral variables appeared to predict
compliance or persistence for the TE patients.
Conclusion: Among the TN, injection competency at baseline and improvement over the first month of use were
significant predictors of compliance and persistence to GA at 12 weeks.Improving self-injection competence should
be a priority when planning interventions for TN patients. Behavioral factors predicting compliance and persistence
among TE patients require further study. (number NCT00238654)


Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A


[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


porn sex

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

Gaziantep Escort

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A


[email protected]

1-702-714-7001Extn: 9037


James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

mp3 indir

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals


Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T


[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version